Last reviewed · How we verify
Hyoscine N Butylbromide
Hyoscine N Butylbromide, marketed by Assiut University, is an established drug in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing revenue generation. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Hyoscine N Butylbromide |
|---|---|
| Also known as | Buscopan |
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Valethamate Bromide Versus Hyoscine Butyl Bromide in Reducing Labour Duration Among Primigravida (NA)
- Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography (NA)
- A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures (NA)
- Motion Sickness Medications and Vestibular Time Constant (PHASE4)
- Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance Imaging (NA)
- The Effect of Hyoscine-n-butylbromide on Nausea and Pain in Laparoscopic Cholecystectomy (PHASE4)
- Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair (PHASE4)
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyoscine N Butylbromide CI brief — competitive landscape report
- Hyoscine N Butylbromide updates RSS · CI watch RSS
- Assiut University portfolio CI